ACD Labs Logo


Practical Considerations for Improving High Throughput Synthesis

April 28, 2020, 10:00 AM EST | 4:00 PM CET

If you are currently involved in high throughput (HT)/parallel synthesis, looking to improve automation productivity gains, or considering investments in automation; don't miss this webinar!

Traditionally, the drivers for high throughput experimentation are the desire for increased productivity (doing more, faster) and profitability (more cost effective and shorter discovery-to-commercialization timelines). Unfortunately, the lack of integration of the tools to get from experimental design to the final decision mean scientists spend too much time on tedious, error-prone tasks.

Do you spend time transcribing information between software applications, and configuring equipment?

Are you manually tracing analytical results back to experiments?

See how a new software application—Katalyst D2D—gets you from design to decision faster than ever before by empowering you to:

Hear how scientist are enjoying significant results by deploying this application!


Andrew Anderson

Andrew Anderson currently leads software development efforts as VP of Innovation and Informatics Strategy at ACD/Labs. Prior to ACD/Labs, Andrew worked in Technology Scouting at PepsiCo—with responsibilities in Technology Assessment, Licensing, and Commercialization. Andrew has also served in a variety of Sales Management, Business Development, and Strategic Partnership roles in the Scientific Software industry. Andrew earned a B.Sc in Chemistry and MBA from San Diego State University and started his professional career as an Analytical Chemist and Regulatory CMC Specialist at Pfizer.


Kevin Arendt earned his PhD in Organic Chemistry in 2016 at Princeton University working with Abigail Doyle studying transition metal catalysis. He then started at GlaxoSmithKline working in the area of high throughput experimentation and automation geared towards enabling discovery chemistry programs. In 2019 Kevin joined Bristol-Myers Squibb (then Heritage Celgene) working in the Drug Substance Development group. One of Kevin's key initiatives is to promote end-user HTE use by developing low-barrier solutions to the design and execution of experiments, with Katalyst providing key support to these functions.


Sanji Bhal

Sanji Bhal is the Director of Marketing & Communications at ACD/Labs. Prior to joining ACD/Labs she was a lab-coat wearing medicinal chemist at Signalgene Inc., where she pursued her ongoing interest in cancer research, followed by a stint with the CRO NAEJA Pharmaceuticals. Sanji began her career in the U.K., completing her Ph.D. in synthetic organic chemistry at the University of Reading, and a post-doctoral fellowship at Cancer Research UK. Today Sanji is passionate about understanding the challenges still faced by scientists and R&D organizations, and helping to 'match-make' their needs with the tools available to support their innovations.